Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-miR-452-5p
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Experimental (commonly In Vitro Or In Vivo In Animal Models; Intended For Development As Systemic, E.g. Intravenous, Or Local Administration Depending On Disease)
01
Overview
Anti-miR-452-5p refers to a synthetic oligonucleotide that specifically binds to and inhibits the function of microRNA-452-5p (miR-452-5p). MiR-452-5p is a microRNA implicated as an oncogene or tumor suppressor in various human cancers and diseases, including colorectal cancer, breast cancer, prostate cancer, renal cancer, and others. Inhibition of miR-452-5p with anti-miR-452-5p has been shown in preclinical models to reduce cancer cell proliferation, migration, and chemoresistance, and to enhance apoptosis, primarily by derepressing targets such as PKN2, DUSP6, and RGS2, thereby affecting key signaling pathways like ERK/MAPK and Wnt/β-catenin. Preclinical studies also implicate miR-452-5p in acute kidney injury (AKI), ulcerative colitis, and pancreatic endocrine dysfunction, with anti-miR-452-5p offering potential as a targeted RNA-based therapeutic in these settings[1][3][4][6].
- Other names
- miR-452-5p inhibitormiR452-5p inhibitormiR 452-5p inhibitor
Beyond the preview
Go deeper on anti-miR-452-5p.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-miR-452-5p.